Literature DB >> 17896346

The neuropsychology of ecstasy (MDMA) use: a quantitative review.

Konstantine K Zakzanis1, Zachariah Campbell, Diana Jovanovski.   

Abstract

A growing number of empirical studies have found varying neuropsychological impairments associated with use of 3,4-methylenedioxymethamphetamine (MDMA) use. We set out to determine to what extent neuropsychological abilities are impaired in MDMA users. To do so, meta-analytical methods were used to determine the magnitude of neuropsychological impairment in MDMA users across pre-specified cognitive domains. We found that cognitive impairment secondary to recreational drug use may result in what might be described as small-to-medium effects across all cognitive domains with learning and memory being most impaired. We also found that total lifetime ingestion of MDMA appears to be negatively associated with performance on tasks ranging from attention and concentration to learning and memory. Implications and limitations of these findings are discussed. Copyright 2007 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17896346     DOI: 10.1002/hup.873

Source DB:  PubMed          Journal:  Hum Psychopharmacol        ISSN: 0885-6222            Impact factor:   1.672


  27 in total

1.  Prospective memory deficits in Ecstasy users: effects of longer ongoing task delay interval.

Authors:  Michael Weinborn; Steven Paul Woods; Claire Nulsen; Katherine Park
Journal:  J Clin Exp Neuropsychol       Date:  2011-11-03       Impact factor: 2.475

2.  Basal functioning of the hypothalamic-pituitary-adrenal (HPA) axis and psychological distress in recreational ecstasy polydrug users.

Authors:  Mark A Wetherell; Catharine Montgomery
Journal:  Psychopharmacology (Berl)       Date:  2013-11-05       Impact factor: 4.530

Review 3.  Differential effects of ecstasy on short-term and working memory: a meta-analysis.

Authors:  Claire E Nulsen; Allison M Fox; Geoffrey R Hammond
Journal:  Neuropsychol Rev       Date:  2010-02-16       Impact factor: 7.444

4.  Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users.

Authors:  Una D McCann; Robert R Edwards; Michael T Smith; Kristen Kelley; Michael Wilson; Francis Sgambati; George Ricaurte
Journal:  Psychopharmacology (Berl)       Date:  2011-05-21       Impact factor: 4.530

5.  Sleep apnea in young abstinent recreational MDMA ("ecstasy") consumers.

Authors:  Una D McCann; Francis P Sgambati; Alan R Schwartz; George A Ricaurte
Journal:  Neurology       Date:  2009-12-02       Impact factor: 9.910

Review 6.  A structured review of reasons for ecstasy use and related behaviours: pointers for future research.

Authors:  Gjalt-Jorn Ygram Peters; Gerjo Kok
Journal:  BMC Public Health       Date:  2009-07-13       Impact factor: 3.295

7.  Differential changes in mesolimbic dopamine following contingent and non-contingent MDMA self-administration in mice.

Authors:  María Juliana Orejarena; Fernando Berrendero; Rafael Maldonado; Patricia Robledo
Journal:  Psychopharmacology (Berl)       Date:  2009-06-04       Impact factor: 4.530

8.  Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study.

Authors:  Susana de Sola; Thais Tarancón; Jordi Peña-Casanova; Josep María Espadaler; Klaus Langohr; Sandra Poudevida; Magí Farré; Antonio Verdejo-García; Rafael de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2008-06-26       Impact factor: 4.530

9.  Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study.

Authors:  Benjamin Becker; Daniel Wagner; Philip Koester; Katja Bender; Christoph Kabbasch; Euphrosyne Gouzoulis-Mayfrank; Jörg Daumann
Journal:  Psychopharmacology (Berl)       Date:  2012-09-23       Impact factor: 4.530

10.  Dose-related effects of MDMA on psychomotor function and mood before, during, and after a night of sleep loss.

Authors:  Wendy M Bosker; Kim P C Kuypers; Silke Conen; Johannes G Ramaekers
Journal:  Psychopharmacology (Berl)       Date:  2010-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.